Indian startups plan affordable CAR-T therapies—first for domestic use, then for the global market.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jayaraman, K. Cut-price CAR-T cell therapies top India’s biotech agenda. Nat Biotechnol 37, 1388–1389 (2019). https://doi.org/10.1038/s41587-019-0346-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-019-0346-1
- Springer Nature America, Inc.
This article is cited by
-
Equitable access to cell and gene therapies in South Africa: opportunities and hurdles
Gene Therapy (2023)
-
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Signal Transduction and Targeted Therapy (2022)